πŸ‡ΊπŸ‡Έ FDA
Patent

US 9399774

Modulation of transthyretin expression

granted A61KA61K31/712A61P

Quick answer

US patent 9399774 (Modulation of transthyretin expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61K, A61K31/712, A61P, A61P1/08, A61P1/10